Meral Beksac
Ankara Üniversitesi
H-index: 65
Asia-Turkey
Top articles of Meral Beksac
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study | Frontiers in Cardiovascular Medicine | Yüksel Çavuşoğlu İbrahim Başarıcı Omaç Tüfekçioğlu Ebru Özpelit Elif Özdemir | 2024 |
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect … | Leukemia & Lymphoma | Katja Weisel Meletios A Dimopoulos Meral Beksac Xavier Leleu Joshua Richter | 2024/2/10 |
Latest Research | Scientific Advisory Panel | ||
Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells | Chemical Biology & Drug Design | Dilara Akcora‐Yildiz Tulin Ozkan Bekir Cetintav Yunus Yukselten Seyma Calis | 2024/2 |
IN VIVO AND IN VITRO EFFECTS OF CORD BLOOD HEMATOPOIETIC STEM AND PROGENITOR CELL (HSPC) EXPANSION USING VALPROIC ACID AND/OR NICOTINAMIDE | Current Research in Translational Medicine | Emine Begum Gencer Hasan Yalim Akin Selami Kocak Toprak Eylul Turasan Mahsa Yousefzadeh | 2024/3/1 |
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma … | Bone Marrow Transplantation | Meral Beksac Diderik-Jan Eikema Linda Koster Cyrille Hulin Xavier Poiré | 2024/1/31 |
Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases | British Journal of Haematology | Erman Akkus Timur Tuncalı Hasan Yalım Akın Yıldız Aydın Sevgi Kalayoğlu Beşışık | 2024/3 |
Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma | New England Journal of Medicine | Pieter Sonneveld Meletios A Dimopoulos Mario Boccadoro Hang Quach P Joy Ho | 2024/1/25 |
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment | Clinical Lymphoma Myeloma and Leukemia | Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon | 2024/3/1 |
The Many Faces of Multiple Myeloma (MM) | Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology | Asya Tuğçe Bol Güldane Cengiz Seval Meral Beksaç Işınsı Kuzu | 2023/7/27 |
P956: VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM (R2-ISS) FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA IN A REAL WORLD COHORT: AN ANALYSIS BY THE BALKAN … | HemaSphere | Efstathios Kastritis Eirini Katodritou Sorina Badelita Jelena Bila Güldane Cengiz Seval | 2023/8/1 |
Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT | Bone marrow transplantation | Meral Beksac Simona Iacobelli Linda Koster Jan Cornelissen Laimonas Griskevicius | 2023/9 |
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety … | Clinical Lymphoma Myeloma and Leukemia | Meral Beksac Guldane Cengiz Seval Derya Koyun Pervin Topcuoglu Meltem-Kurt Yuksel | 2023/3/1 |
P-132 Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma | Clinical Lymphoma Myeloma and Leukemia | Guldane Cengiz Seval Klara Dalva Sule Mine Bakanay Ender Soydan Osman Ilhan | 2023/9/1 |
Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression … | Blood | Meral Beksac Tulin Tuglular Francesca Gay Roberto Mina Eirini Katodritou | 2023/11/28 |
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE | Acta Haematologica | Thomas Weber Sunday Ocheni Mascha Binder Sebastian Theurich Christof Scheid | 2013/4/1 |
P19 EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES | HemaSphere | M Beksac G Cengiz Seval S Civriz Bozdag SK Toprak M Kurt Yuksel | 2023/5/1 |
Isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis | Paul Richardson Aurore Perrot Jesus San Miguel Meral Beksac Ivan Špička | 2023/7/12 | |
P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS | HemaSphere | Philippe Moreau Aurore Perrot Meletios A Dimopoulos Thomas Martin Thierry Facon | 2023/8/1 |
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients | Leukemia | Elias K Mai Thomas Hielscher Uta Bertsch Hans J Salwender Sonja Zweegman | 2023/12/7 |
Co-Authors
